Best-value biological medicines are the clearest near-term medicines productivity play in the NHS

Best-value biological medicines are the clearest near-term medicines productivity play in the NHS

biological medicines should be near the top of the list. That is not because the topic is fashionable. It is because the numbers are unusually clear and the national direction is unusually explicit. NHS England’s commissioning framework for best-value biological medicines notes that eight of the top ten medicines prescribed in hospitals by spend are biological medicines. It also says the NHS spends around £1.4 billion on biological medicines due to lose patent protection by 2028 and estimates that timely uptake of better-value versions could free up up to £1 billion for reinvestment in patient care. The NHS has already demonstrated that the model can work: over the last three years, switches have generated £1.2 billion in total savings, including around £400 million from adalimumab alone. Those are not theoretical gains. They are evidence that the productivity opportunity is real. NHS England has therefore raised the bar. Its framework now sets out an ambition that 100% of new patients should be initiated on the best-value biological medicine, where clinically appropriate, within three months of launch, and that at least 80% of existing patients should be on the best-value option within ten months. It has also prioritised five major biological medicines for national focus — ustekinumab, aflibercept, ocrelizumab, ipilimumab and vedolizumab — based on value, patient volume, pathway opportunity and switching complexity. For provider finance and pharmacy leaders, the implication is straightforward: this is no longer a side programme. It is a test of whether the organisation can turn patent expiry into managed, repeatable value. The trap is to assume that once a biosimilar or other best-value product is available, the savings will materialise automatically. They will not. NHS England’s own framework spends much of its time on implementation rather than market theory, for good reason. The barriers are rarely about awareness. They are about operational execution. A best-value biological switch depends on several moving parts. There must be clarity about which patients are in scope and when. Clinical teams need confidence in the switching approach and appropriate patient communication. Pharmacy and procurement need to be aligned on contracting and product availability. Homecare arrangements may need to change. Finance teams need to understand how the value will flow and whether temporary switching resource is required. Monitoring must be robust enough to show whether the uptake ambition is being met. This is why the most effective organisations treat best-value biological adoption as a programme, not a memo. For a trust CFO or chief pharmacist, the practical playbook is relatively simple. First, select one or two priority molecules rather than trying to manage the whole future market at once. National prioritisation exists precisely to help systems concentrate effort where the value is largest and the implementation case is strongest. Pick the molecule, define the window, and make the expected benefits explicit. Second, build the case around pathway and capacity, not just price difference. Finance teams often reach too quickly for gross savings estimates. But the organisation may need clinic time, pharmacy support, homecare coordination or patient communications resource to switch at pace. NHS England explicitly acknowledges the need for resource enablement and supports financial arrangements that allow provider effort to be recognised. A realistic net-value case will always outperform an inflated gross one. Third, agree a deployment model before launch. Which teams own identification of patients? Which clinical leaders will sponsor the switch? What will be the default for new starts? How will exceptions be managed? What is the expected adoption curve month by month? What reporting line will monitor progress? Organisations that answer these questions late usually discover that the operational friction has already eaten into the available value window. Fourth, align commissioner and provider incentives early. NHS England’s framework emphasises collaborative working and notes that without agreed financial arrangements all savings may accrue to the commissioner even though provider teams do the implementation work. The proposed use of national reference prices for prioritised biologicals is intended partly to solve this by creating a transparent incentive to switch while preserving a margin for clinically appropriate continued use of the reference product. Local leaders should not wait passively for national design to solve all execution issues. They should make the shared-gain conversation part of the early planning. Fifth, track realised value and blockers monthly. Best-value biologicals are ideal candidates for disciplined review because the cohorts, spend and timelines are often clearer than in other medicines optimisation areas. A useful monthly pack should show eligible patients, current uptake, target uptake, value delivered, operational issues, and any clinical or supply concerns that are slowing progress. If a switch is behind plan, the organisation needs to know quickly enough to intervene. There is also a wider strategic reason to take this seriously. Best-value biologicals are one of the clearest examples of how NHS medicines value should work in the next phase: horizon scanning early, implementation planning before market entry, commissioner-provider collaboration, shared use of national tools, and disciplined local execution. Teams that learn to do this well on biologicals will usually become better at other high-value switching and contracting opportunities too. The NHS does not often get a productivity opportunity that is this visible, this policy-backed and this measurable. That does not make delivery easy. It makes it worth managing properly. Boards should therefore resist two opposite mistakes. One is complacency: assuming that because the policy exists, the value will appear. The other is over-complexity: surrounding the opportunity with so much governance and local reinvention that the implementation window closes. The better path is practical. Pick the molecule. Define the case. Resource the switch. Measure the rollout. Review the variance. Reinvest the gain. Best-value biological medicines are not just another pharmacy workstream. In the current NHS environment, they are one of the most credible tests of whether providers and commissioners can convert medicines policy into real financial headroom without compromising care. That is exactly why they deserve board attention now. Research base used in drafting